Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Glioma 2Brain Neoplasms 2Waldenstrom Macroglobulinemia 1Prostatic Neoplasms 1Oligodendroglioma 1Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Gliosarcoma 1Glioblastoma 1Astrocytoma 1

Interventions

Rituximab 49fludarabine phosphate 32Cyclophosphamide 30Whole-Body Irradiation 26Peripheral Blood Stem Cell Transplantation 25Mycophenolic Acid 24Tacrolimus 19Cyclosporine 16Dexamethasone 13Busulfan 13ibrutinib 12Sirolimus 12Bortezomib 11Antilymphocyte Serum 11Melphalan 10Etoposide 10Calcium Dobesilate 10Methotrexate 8Lenalidomide 8Cyclosporins 8idelalisib 7Everolimus 6Indium 5Filgrastim 5thymoglobulin 4ibritumomab tiuxetan 4carfilzomib 4Vincristine 4Prednisone 4In Situ Hybridization, Fluorescence 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Waldenstrom Macroglobulinemia × perifosine × Clear all
NCT00422656 2017-12-26

Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

Dana-Farber Cancer Institute

Phase 2 Completed
37 enrolled 10 charts
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡